What's new? Log in Free sign up

AstraZeneca (AZN)

Company Profile

Company profile

Ticker

AZN, AZNCF

Exchange

Website

www.astrazeneca.com

CEO

Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • AbbVie • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Bausch Health Companies • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

ZENECA GROUP PLC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

AZN stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Imfinzi Improved DFS In Early Bladder Cancer

Enhertu Improved PCR In Early-stage Breast Cancer

Calquence Combination Approved In Eu for 1L MCL

Breztri Met Primary Endpoints In PH3 Asthma Trials

Director/pdmr Shareholding

Total Voting Rights

Fixed-duration Calquence Recommended In Eu for CLL

Update on CAPITELLO-280 Phase III Trial

1ST Quarter Results

Enhertu Combination Improved PFS In 1L HER2+ MBC

Transcripts

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

BlackRock, Inc.

CONDUIT PHARMACEUTICALS INC.

Monopar Therapeutics

CONDUIT PHARMACEUTICALS INC.

Annual report of employee stock purchases

ADC Therapeutics SA

Notice of proposed sale of securities

Financial summary

Financial statements Chart AZN financial data

Quarter (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from AstraZeneca earnings reports.

Institutional ownership, Q4 2024

AZN institutional ownership history Ownership history

0.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	2	3	-33.3%
Opened positions	0	2	EXIT
Closed positions	1	0	NEW
Increased positions	0	0
Reduced positions	1	1	–

13F shares	Current	Prev Q	Change
Total value	28.26 bn	198.68 mm	+14123.6%
Total shares	216.98 k	263.47 k	-17.6%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Boston Common Asset Management	216.78 k	$28.26 bn	-17.3%
FNY Investment Advisers	200.00	$2.09 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Boston Common Asset Management	216.78 k	-45.50 k	-17.3%
Eagle Bay Advisors	0.00	-1.00 k	EXIT
FNY Investment Advisers	200.00	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.

P/E Ratio Insights for AstraZeneca

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.

AstraZeneca And Daiichi Sankyo's ENHERTU Followed By THP Shows Improved Safety Profile Vs. Standard Of Care

Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model

Press releases

From Benzinga Pro

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025

New data for AIRSUPRA and BREZTRI highlight progress in advancing asthma and COPD care globally AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

Patients lived significantly longer without high-risk disease recurrence or progression after one year of IMFINZI treatment plus Bacillus Calmette-Guérin (BCG) induction and maintenance therapy vs. BCG alone Positive

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

AstraZeneca and Daiichi Sankyo's ENHERTU followed by THP showed an improved safety profile vs. standard of care First Phase III trial to demonstrate benefit of ENHERTU in early breast cancer Positive high-level

ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial

BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.